---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018242"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T11:48:12.071088+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Intelligent Bio Solutions Q3 revenue up 80% to $0.82M; cash $9.4M after $10.76M capital raise

## Summary
- Revenue of $0.82M for Q3 FY2024, up 80% YoY; nine-month revenue $2.38M, up 193%.
- Net loss for Q3 was $2.98M, including $0.54M non-cash items; nine-month net loss decreased to $7.37M.
- Cash and equivalents $9.4M as of March 31, 2024, up from $1.1M at Dec 31, 2023, after net capital raise of ~$10.76M.
- FDA 510(k) clinical studies with Cliantha Research underway; submission expected by end of 2024, US entry planned in 2025.
- Secured 26 new accounts during quarter, representing ~16,779 employees; European patent granted for DSR-Plus Cartridge Reader.

## SEC filing metadata
- accession: 0001493152-24-018242
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315224018242/0001493152-24-018242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315224018242/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018242
- JSON: https://secwatch.observer/filing/0001493152-24-018242.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018242.txt

## Key facts
- Earnings Releases
  INTELLIGENT BIO SOLUTIONS INC. reported nine months ended March 31, 2024 results: revenue $2.38 million, net income $7.37 million.
  - Period: nine months ended March 31, 2024
  - Revenue: $2.38 million
  - Net income: $7.37 million
  - Result: reported results
  source text: Total revenue for the nine months ended March 2024 was $2.38 million, an increase of 193% compared to the same period the year prior.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725430/000149315224018242/0001493152-24-018242-index.htm
- Earnings Releases
  INTELLIGENT BIO SOLUTIONS INC. reported fiscal third quarter ended March 31, 2024 results: revenue $0.82 million, net income $2.98 million.
  - Period: fiscal third quarter ended March 31, 2024
  - Revenue: $0.82 million
  - Net income: $2.98 million
  - Result: reported results
  source text: Total revenues for the fiscal third quarter were $0.82 million, an increase of 80% compared to the same period the year prior.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725430/000149315224018242/0001493152-24-018242-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.